search
Back to results

Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1

Primary Purpose

Adherence, Depression, Heroin Dependence

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CBT-AD
ETAU
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adherence

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: HIV seropositive Currently enrolled in methadone maintenance treatment for at least one month Current major or subsyndromal depression (subsyndromal depression is defined by major depression that does not meet full diagnostic criteria but with a clinical global impression of severity (CGI-S) of 2 (mildly ill)) Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary care provider. Between the ages of 18 and 65. Exclusion Criteria: Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania), or other Axis I psychiatric disorders (other than depression) that would interfere with the ability to participate (i.e. CGI-S >6) Unable or unwilling to provide informed consent. Currently in cognitive behavioral therapy for depression.

Sites / Locations

  • Massachusetts General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CBT-AD

ETAU

Arm Description

Cognitive behavioral therapy for adherence and depression

Enhanced treatment as usual

Outcomes

Primary Outcome Measures

Percent Medication Adherence at 3-month Follow-up Assessment
Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
Percent Medication Adherence at 12-month Follow-up Assessment
Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.

Secondary Outcome Measures

Clinician-assessed Depression Rating at 3 Month Follow-up Assessment
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
HIV Viral Load at 12-month Follow-up Assessment
HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.
CD4+ Lymphocyte Count at 12-month Follow-up Assessment.
CD4+ lymphocyte cell count at 12-month follow-up assessment.
Clinician-assessed Depression at 12-month Follow-up Assessment
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
HIV Viral Load at 3-month Follow-up Assessment
HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.
CD4+ Lymphocyte Count at 3-month Follow-up Assessment.
CD4+ lymphocyte cell count at 3-month follow-up assessment.

Full Information

First Posted
September 20, 2005
Last Updated
December 7, 2017
Sponsor
Massachusetts General Hospital
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00218634
Brief Title
Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1
Official Title
CBT for Depression & Adherence in HIV Methadone Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
February 2005 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001). Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.
Detailed Description
Symptoms of depression (i.e. low motivation, poor concentration, loss of interest, sad mood, suicidal ideation) that occur in the context of substance abuse or dependence can interfere with self-care behaviors necessary for maintaining HIV care, as well as interfere with potential benefit from an intervention that focuses on adherence alone. We hypothesize that teaching skills to cope with depression will improve the outcome from an adherence intervention to promote healthier living with HIV, in HIV+ opioid dependent individuals in methadone maintenance treatment. Overview of Research Plan. Patients who are HIV positive and who are receiving methadone maintenance for opioid dependence will be randomized to treatment with either: (1) CBT, a combination of CBT for depression and HIV medication adherence, including a single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments or (2) the single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments. Participants will be followed for one-year post-randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adherence, Depression, Heroin Dependence, Methadone, Motivational Interviewing, Substance-Related Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
89 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CBT-AD
Arm Type
Experimental
Arm Description
Cognitive behavioral therapy for adherence and depression
Arm Title
ETAU
Arm Type
Active Comparator
Arm Description
Enhanced treatment as usual
Intervention Type
Behavioral
Intervention Name(s)
CBT-AD
Intervention Description
Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
Intervention Type
Behavioral
Intervention Name(s)
ETAU
Intervention Description
Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
Primary Outcome Measure Information:
Title
Percent Medication Adherence at 3-month Follow-up Assessment
Description
Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
Time Frame
3-month assessment
Title
Percent Medication Adherence at 12-month Follow-up Assessment
Description
Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
Time Frame
12-month follow-up assessment
Secondary Outcome Measure Information:
Title
Clinician-assessed Depression Rating at 3 Month Follow-up Assessment
Description
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
Time Frame
3 month follow-up
Title
HIV Viral Load at 12-month Follow-up Assessment
Description
HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.
Time Frame
12-month follow-up assessment
Title
CD4+ Lymphocyte Count at 12-month Follow-up Assessment.
Description
CD4+ lymphocyte cell count at 12-month follow-up assessment.
Time Frame
12-month follow-up assessment
Title
Clinician-assessed Depression at 12-month Follow-up Assessment
Description
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
Time Frame
12-month follow-up assessment
Title
HIV Viral Load at 3-month Follow-up Assessment
Description
HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.
Time Frame
3-month assessment
Title
CD4+ Lymphocyte Count at 3-month Follow-up Assessment.
Description
CD4+ lymphocyte cell count at 3-month follow-up assessment.
Time Frame
3-month assessment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HIV seropositive Currently enrolled in methadone maintenance treatment for at least one month Current major or subsyndromal depression (subsyndromal depression is defined by major depression that does not meet full diagnostic criteria but with a clinical global impression of severity (CGI-S) of 2 (mildly ill)) Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary care provider. Between the ages of 18 and 65. Exclusion Criteria: Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania), or other Axis I psychiatric disorders (other than depression) that would interfere with the ability to participate (i.e. CGI-S >6) Unable or unwilling to provide informed consent. Currently in cognitive behavioral therapy for depression.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven Safren, Ph.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22545737
Citation
Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012 Jun;80(3):404-15. doi: 10.1037/a0028208. Epub 2012 Apr 30.
Results Reference
derived

Learn more about this trial

Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1

We'll reach out to this number within 24 hrs